Cornerstone Capital Management Holdings LLC. increased its stake in Gilead Sciences (NASDAQ:GILD) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 782,405 shares of the biopharmaceutical company’s stock after purchasing an additional 25,652 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.06% of Gilead Sciences worth $56,050,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. boosted its stake in Gilead Sciences by 1.5% in the fourth quarter. BlackRock Inc. now owns 103,797,247 shares of the biopharmaceutical company’s stock valued at $7,436,033,000 after buying an additional 1,552,359 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 1.5% in the fourth quarter. Bank of New York Mellon Corp now owns 30,542,928 shares of the biopharmaceutical company’s stock valued at $2,188,095,000 after buying an additional 446,263 shares in the last quarter. Parnassus Investments CA boosted its stake in Gilead Sciences by 2.5% in the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after buying an additional 464,609 shares in the last quarter. Geode Capital Management LLC boosted its stake in Gilead Sciences by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 15,849,063 shares of the biopharmaceutical company’s stock valued at $1,133,346,000 after buying an additional 379,867 shares in the last quarter. Finally, Capital International Investors boosted its stake in Gilead Sciences by 86.6% in the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after buying an additional 5,205,983 shares in the last quarter. Institutional investors own 78.35% of the company’s stock.
Several analysts recently weighed in on the company. Credit Suisse Group set a $80.00 price objective on Gilead Sciences and gave the company a “hold” rating in a research note on Tuesday. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 price objective on the stock in a research note on Thursday. Barclays reaffirmed an “overweight” rating and issued a $95.00 price objective (up from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Finally, TheStreet lowered Gilead Sciences from a “b-” rating to a “c” rating in a research note on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $88.65.
Shares of GILD opened at $74.44 on Friday. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. The stock has a market cap of $98,401.56, a PE ratio of 8.70, a P/E/G ratio of -1.74 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same period last year, the company earned $2.70 earnings per share. The firm’s revenue was down 18.7% compared to the same quarter last year. research analysts anticipate that Gilead Sciences will post 6.19 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.06%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
In other news, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the transaction, the chief financial officer now directly owns 23,749 shares in the company, valued at $1,907,282.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Francis Cogan sold 5,833 shares of the firm’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $80.93, for a total value of $472,064.69. The disclosure for this sale can be found here. Insiders have sold 308,600 shares of company stock valued at $24,328,226 over the last 90 days. 1.30% of the stock is owned by corporate insiders.
WARNING: This piece of content was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/04/20/gilead-sciences-gild-position-lifted-by-cornerstone-capital-management-holdings-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.